Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06659211

Effectiveness of Mentalization-based Therapy (MBT)

The effects of psychological treatment, mentalization-based therapy, will be studied among persons with mental disorders seeking help from mental health care services.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Background: Mentalization-based therapy (MBT) has a growing evidence base as a group treatment, and research on MBT as an individual treatment is needed. This study will provide crucial new information on its effectiveness and usability in everyday patient care.

Methods: The study design will be an non-randomized clinical pilot study. We will study the effectiveness of MBT and analyze which factors are associated with better effectiveness. The length of intervention will be 12 months. The primary outcome measure is the change in psychological symptoms and well-being from the beginning to the end of MBT treatment, measured by CORE-OM. Secondary outcomes include several measures of symptoms, functioning, quality of life, and mentalization. Outcomes will be assessed at 6, 12 and 18 months. The study group will comprise of 64 patients receiving MBT. For comparison, patient group (n=64) with similar characteristics (age, gender, diagnosis) receiving treatment as usual (TAU) in psychiatric services will be ascertained from medical records, and their outcomes after 12 months of treatment will be compared to that of MBT -group.

Intervention / Treatment: Behavioral: Mentalization-based treatment/therapy

Participation criteria: Patients are not strictly limited to a specific disease/diagnostic group. This choice has been made because there is an increasing need in the mental health care for the treatment and therapy of this multi-symptom and severely symptomatic patient group, which also makes the results of the study more applicable to a real life. Patients will be selected for the MBT and TAU based on inclusion and exclusion criteria and patients preference. In addition, the selection to MBT will be made by a trained MBT therapist, who will assess the patient's suitability for MBT (e.g., patient willing to engage in active psychotherapeutic work, interested in the inner world of experience, willing to work interactively).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

MBT Group:

  • Age 18-64 years.
  • Severe psychological symptoms, decreased functioning ability for long-term
  • Challenges with interpersonal relationships and emotional regulation
  • Patients willing to receive MBT
  • At least two of the following:
  • Depression (diagnosis codes: F31.3-F31.5, F32.0-F32.9, F33.3-F33.9, F34.1) or anxiety disorder (diagnosis codes: F40-F48)
  • Trauma background either as diagnosis or as need for treatment
  • Signs of personality disorder (suspected or diagnosed)

TAU group:

  • Age 18-64 years.
  • Severe psychological symptoms, decreased functioning ability for long-term
  • Challenges with interpersonal relationships and emotional regulation
  • At least two of the following
  • Depression (diagnosis codes: F31.3-F31.5, F32.0-F32.9, F33.3-F33.9, F34.1) or anxiety disorder (diagnosis codes: F40-F48)
  • Trauma background either as diagnosis or as need for treatment
  • Signs of personality disorder (suspected or diagnosed)

Exclusion criteria

MBT Group:

  • Active substance use disorder (i.e., intoxication F1x.0, active dependence F1x.24, Continuous use F1x.25), a physiological withdrawal state F1x.3 and F1x.4, or psychotic disorder F1x.5).
  • Acute psychosis (defined as the recent onset of severe psychotic symptoms that interfere with functioning and are not yet in a therapeutic state. Non-acute psychotic symptoms are not exclusionary)
  • Disorder requiring inpatient treatment
  • Previously received MBT
  • Currently receiving psychotherapeutic treatment (previous psychotherapeutic treatment is not an exclusion)

The exclusion criteria, therefore, do not exclude psychotic disorders or any other psychiatric illness (except substance abuse disorders).

TAU group:

  • Active substance use disorder (i.e., intoxication F1x.0, active dependence F1x.24, Continuous use F1x.25), a physiological withdrawal state F1x.3 and F1x.4, or psychotic disorder F1x.5).
  • Acute psychosis (defined as the recent onset of severe psychotic symptoms that interfere with functioning and are not yet in a therapeutic state. Non-acute psychotic symptoms are not exclusionary)
  • Disorder requiring inpatient treatment
  • Previously received MBT
  • Intensive psychotherapy (e.g. rehabilitative psychotherapy or similar weekly long-term psychotherapy)

Treatment and study plan

Mentalisation-Based Therapy

Behavioral

MBT is conducted according to the treatment manual developed by Bateman & Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.

Treatment as usual (TAU)

Other

The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.

Primary outcomes

  1. Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM)

    Time frame: baseline, 6, 12 and 18 months

    A self-report measure of psychological distress and symptoms. Higher scores indicates worse outcomes. Includes four main domains: wellbeing, problems, functioning and risk (to self or others).

    Based on detailed instructions on calculating the scores, clinical score minimun 0 and maximum 40.

Secondary outcomes

  1. The Big Five Inventory-2 Extra-Short Form (BFI-2-XS)

    Time frame: baseline, 6, 12 and 18 months

    questionnaire assessing personality

  2. the Inventory of Interpersonal Problems (IIP-32)

    Time frame: baseline, 6, 12 and 18 months

    Questionnaire on interpersonal problems

  3. Experiences in Close Relationships Short version (ECR-S)

    Time frame: baseline, 6, 12, and 18 months

    Measures experiences in close relationships

  4. Rosenberg Self-Esteem Scale (RSE)

    Time frame: baseline, 6, 12, and 18 months

    Questionnaire on self-esteem

  5. Emotion Regulation Questionnaire (ERQ)

    Time frame: baseline, 6, 12 and 18 months

    Measure of emotion regulation

  6. The Certainty About Mental States Questionnaire (CAMSQ)

    Time frame: baseline, 6, 12 and 18 months

    Questionnaire on perceived capacity of mentalising oneself and others.

  7. The Reflective Functioning Questionnaire (RFQ)

    Time frame: baseline, 6, 12 and 18 months

    a brief measure of reflective functioning, i.e. mentalizing

  8. Quality of life

    Time frame: baseline, 6, 12 and 18 months

    WHO 1 question

  9. The Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: baseline, 12 months

    Interview based rating of depression symptoms and their severity. Minimum: 0 Maximum: 60 Higher scores indicate more severe symptoms.

  10. Social and Occupational Functioning Assessment Scale (SOFAS)

    Time frame: baseline, 12 months

    Clinician/investigator rated measure of social and occupational functioning. Minimum value: 0 (Inadequate information), 1 (worst functioning, unable to function, persistent inability) Maximum value: 100 (Superior functioning in a wide range of activities)

  11. Clinical Global Impression- Severity scale (CGI-S)

    Time frame: baseline, 12 months

    Clinical Global Impression of the severity of illness. Minimum value: 1 (normal, not at all ill) Maximum value: 7 (amongst the most severely ill)

  12. Working Alliance Inventory (WAI)

    Time frame: baseline, 6 and 12 months

    Questionnaire on therapeutic alliance. Higher scores indicate better alliance.

  13. Suicidality

    Time frame: from baseline to 18 months

    from questionnaires and medical records

  14. Patient experiences of the treatment

    Time frame: 6 and 12 months

    questions on how the patient has experienced the intervention, and if he/she has experienced the treatment as beneficial

  15. Experiences of recovery

    Time frame: 12 and 18 months

    Questions on experience of change of health status and recovery

Other outcomes

  1. Physical symptoms and illnesses

    Time frame: from baseline to 12 months

    Information collected from the medical records. Data on physical symptoms or diagnosed physical illnesses, that the patient complains or seeks help will be collected from the medical records (visits to mental health care and somatic care).

  2. Need of psychiatric services

    Time frame: from baseline to 12 months

    Number of outpatient, inpatient and emergency visits. Data from medical records.

  3. Use of medication

    Time frame: from baseline to 12 months

    Use of psychiatric medications. Data from medical records.

Study contacts

Contact information is provided by the study sponsor or research team.

Jenni Vähä, MSc

CONTACT

[email protected]

800-555-5555

Sponsors and collaborators

Lead sponsor

Oulu University Hospital

Other

Collaborators

  • University of Oulu

Registry information

Official study title

Effectiveness of Mentalization-based Therapy (MBT) as Part of a Stepped Mental Health Care in Finland - a Pilot Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Oct 26, 2024
Registry last updated
Apr 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.